ID: ALA3900595

Max Phase: Preclinical

Molecular Formula: C21H25N2O4PS2

Molecular Weight: 464.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)CC(N1C(=O)/C(=C/c2ccc(N(C)C)c3ccccc23)SC1=S)P(=O)(O)O

Standard InChI:  InChI=1S/C21H25N2O4PS2/c1-13(2)11-19(28(25,26)27)23-20(24)18(30-21(23)29)12-14-9-10-17(22(3)4)16-8-6-5-7-15(14)16/h5-10,12-13,19H,11H2,1-4H3,(H2,25,26,27)/b18-12-

Standard InChI Key:  MZIRQTRYBCGDTO-PDGQHHTCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.55

Molecular Weight (Monoisotopic): 464.0993

AlogP: 4.66

#Rotatable Bonds: 6

Polar Surface Area: 81.08

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.49

CX Basic pKa: 4.82

CX LogP: 2.70

CX LogD: 1.88

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.37

Np Likeness Score: -1.03

References

1. Slepikas L, Chiriano G, Perozzo R, Tardy S, Kranjc A, Patthey-Vuadens O, Ouertatani-Sakouhi H, Kicka S, Harrison CF, Scrignari T, Perron K, Hilbi H, Soldati T, Cosson P, Tarasevicius E, Scapozza L..  (2016)  In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA.,  59  (24): [PMID:26730986] [10.1021/acs.jmedchem.5b01620]

Source

Source(1):

• Scientific Literature